JP2019515000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515000A5 JP2019515000A5 JP2018559272A JP2018559272A JP2019515000A5 JP 2019515000 A5 JP2019515000 A5 JP 2019515000A5 JP 2018559272 A JP2018559272 A JP 2018559272A JP 2018559272 A JP2018559272 A JP 2018559272A JP 2019515000 A5 JP2019515000 A5 JP 2019515000A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- halo
- substituted
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 125000001188 haloalkyl group Chemical group 0.000 claims description 34
- 125000001475 halogen functional group Chemical group 0.000 claims description 34
- -1 homopiperidinyl Chemical group 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000003112 inhibitor Substances 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000003386 piperidinyl group Chemical group 0.000 claims description 18
- 125000002883 imidazolyl group Chemical group 0.000 claims description 16
- 125000002393 azetidinyl group Chemical group 0.000 claims description 14
- 125000002757 morpholinyl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000004193 piperazinyl group Chemical group 0.000 claims description 14
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 12
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 10
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
- 208000031886 HIV Infections Diseases 0.000 claims description 8
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 8
- 239000002777 nucleoside Substances 0.000 claims description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 208000037357 HIV infectious disease Diseases 0.000 claims description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 6
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 229940122440 HIV protease inhibitor Drugs 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 230000034303 cell budding Effects 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims description 4
- 229960002542 dolutegravir Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000002835 hiv fusion inhibitor Substances 0.000 claims description 4
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000000034 method Methods 0.000 description 4
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662334711P | 2016-05-11 | 2016-05-11 | |
| US62/334,711 | 2016-05-11 | ||
| PCT/IB2017/052700 WO2017195112A1 (en) | 2016-05-11 | 2017-05-09 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515000A JP2019515000A (ja) | 2019-06-06 |
| JP2019515000A5 true JP2019515000A5 (enExample) | 2020-04-23 |
Family
ID=58745294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559272A Ceased JP2019515000A (ja) | 2016-05-11 | 2017-05-09 | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20200325127A1 (enExample) |
| EP (1) | EP3455217A1 (enExample) |
| JP (1) | JP2019515000A (enExample) |
| WO (1) | WO2017195112A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019515003A (ja) * | 2016-05-11 | 2019-06-06 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
| EP3565810A1 (en) * | 2017-01-03 | 2019-11-13 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| CA2705312C (en) | 2007-11-15 | 2013-06-25 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| CA2705318C (en) | 2007-11-15 | 2013-12-31 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| ES2463720T3 (es) | 2007-11-16 | 2014-05-29 | Gilead Sciences, Inc. | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| EA201200631A1 (ru) | 2007-11-16 | 2012-11-30 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| US8338441B2 (en) * | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| US20120316161A1 (en) | 2009-12-23 | 2012-12-13 | Katholieke Universiteit Leuven | Novel antiviral compounds |
| US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US8629276B2 (en) | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| EP2970298A1 (en) | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| EP2970274B1 (en) | 2013-03-14 | 2017-03-01 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US9193720B2 (en) * | 2014-02-20 | 2015-11-24 | Bristol-Myers Squibb Company | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| TWI657086B (zh) * | 2015-08-11 | 2019-04-21 | 英商Viiv醫療保健英國(No.5)有限公司 | 做為人類免疫缺陷病毒複製抑制劑之５－（ｎ－苯甲基四氫異喹啉－６－基）吡啶－３－基乙酸衍生物 |
| CN108137552A (zh) * | 2015-08-12 | 2018-06-08 | Viiv保健英国第五有限公司 | 作为人免疫缺陷病毒复制的抑制剂的5-(n-稠合三环芳基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物 |
| CA2995042A1 (en) * | 2015-08-12 | 2017-02-16 | VIIV Healthcare UK (No.5) Limited | 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| TW201718537A (zh) * | 2015-08-12 | 2017-06-01 | Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 | 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物 |
| JP2019515003A (ja) * | 2016-05-11 | 2019-06-06 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
| EP3455214A1 (en) * | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
-
2017
- 2017-05-09 US US16/094,567 patent/US20200325127A1/en not_active Abandoned
- 2017-05-09 EP EP17724920.8A patent/EP3455217A1/en not_active Withdrawn
- 2017-05-09 WO PCT/IB2017/052700 patent/WO2017195112A1/en not_active Ceased
- 2017-05-09 JP JP2018559272A patent/JP2019515000A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512511A5 (enExample) | ||
| JP2017526748A5 (enExample) | ||
| JP2016512558A5 (enExample) | ||
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| JP2018522927A5 (enExample) | ||
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| RU2017107715A (ru) | Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека | |
| JP2016512507A5 (enExample) | ||
| JP2017533925A5 (enExample) | ||
| FI3651766T3 (fi) | 4-(4-(4-(((2-(2,6-dioksopiperidin-3-yyli)-l-oksoisoindolin-4-yyli)oksi)metyyli)bentsyyli)piperatsin-1-yyli)-3-fluoribentsonitriili antiproliferatiivisena yhdisteenä | |
| MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2015524841A5 (enExample) | ||
| RU2018106498A (ru) | Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| JP2016516043A5 (enExample) | ||
| JP2020512343A5 (enExample) | ||
| JP2018524390A5 (enExample) | ||
| IL257240A (en) | History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication | |
| JP2016516692A5 (enExample) | ||
| RU2009117705A (ru) | Производные 2-аминокарбонилпиридина | |
| JP2016190843A5 (enExample) | ||
| RU2018106504A (ru) | Производные пиридин 3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| GEP20237476B (en) | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors |